XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 38 filers reported holding XENON PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,938 | -98.0% | 54,140 | +71.9% | 0.04% | +1025.0% |
| Q2 2017 | $99,000 | -21.4% | 31,500 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $126,000 | -48.1% | 31,500 | 0.0% | 0.01% | -58.3% |
| Q4 2016 | $243,000 | -4.7% | 31,500 | 0.0% | 0.01% | -25.0% |
| Q3 2016 | $255,000 | +33.5% | 31,500 | -2.8% | 0.02% | +6.7% |
| Q2 2016 | $191,000 | -46.3% | 32,400 | -36.5% | 0.02% | 0.0% |
| Q1 2016 | $356,000 | -1.7% | 51,000 | +13.3% | 0.02% | -40.0% |
| Q4 2015 | $362,000 | +3.4% | 45,000 | +6.1% | 0.02% | +66.7% |
| Q3 2015 | $350,000 | – | 42,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |